AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Nasdaq Grants PAVmed 180-Day Extension to Meet Minimum Bid Price Rule
ByAinvest
Saturday, Aug 2, 2025 12:31 am ET1min read
PAVmed has been granted a 180-day extension by Nasdaq to regain compliance with the $1.00 minimum bid price rule. The company's shares will continue trading on the Nasdaq Capital Market without immediate delisting risk. PAVmed must achieve a closing bid price of at least $1.00 per share for ten consecutive business days by January 19, 2026.
PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, has been granted a 180-day extension by Nasdaq to regain compliance with the $1.00 minimum bid price rule. The company now has until January 19, 2026, to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days [1].The notification does not immediately affect PAVmed's listing status, and its shares will continue trading on the Nasdaq Capital Market under the symbol "PAVM" [2]. The company has stated its intention to take appropriate actions to cure the deficiency and regain compliance before the extended deadline [3].
PAVmed operates in the medical device, diagnostics, and digital health sectors. Its subsidiaries, Lucid Diagnostics and Veris Health Inc., are developing innovative products for early detection of esophageal precancer and personalized cancer care, respectively. Despite the current compliance issue, the company's shares will continue to be traded on the Nasdaq Capital Market without immediate delisting risk [2].
For more information about PAVmed, please visit pavmed.com. For information about Lucid Diagnostics, please visit luciddx.com. For more information about Veris Health, please visit verishealth.com.
References:
[1] https://www.stocktitan.net/news/PAVM/pa-vmed-granted-180-day-extension-by-nasdaq-to-regain-compliance-tatmgj1ct8a9.html
[2] https://www.gurufocus.com/news/3016409/pavmed-granted-180day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule-pavm-stock-news
[3] https://www.prnewswire.com/news-releases/pavmed-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule-302517016.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet